News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 280016

Thursday, 12/01/2016 12:08:13 PM

Thursday, December 01, 2016 12:08:13 PM

Post# of 347009

Thank you and many are forgetting about the fact that Big Pharma has NEVER seen Sean Parker types just step in and hand over Millions (that used to be Big Pharmas job... taking small biotechs literally by hostage..)

Out of curiosity, whom do you think would be up for such a job, that you believe could lead the PS Targeting effort? : )



I can't think of no one else to take over the helm. At least now, we now for sure that the PS Targeting platform has not been sold for breadcrumbs

I care less about the manipulated pps value at this time, since it fits with my buy low and sell high philosophy... and I'm more concerned about biomarkers and future, real value that PPHM will be worth.

How much did Genentech accept for their complete buyout? $150 Billion plus...and Genentech on steroids is where Peregrine Pharmaceuticals is heading...

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y